A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2.

Zhang, Qian; Zhou, Renpeng; Yang, Jingjing; Dou, Changlin; Gan, Tianyi; Liu, Fujia; Hu, Baihui; Song, Deyong; Lu, Chao; Hu, Wei

Zhang, Qian; Zhou, Renpeng; Yang, Jingjing; Dou, Changlin; Gan, Tianyi; Liu, Fujia; Hu, Baihui; Song, Deyong; Lu, Chao; Hu, Wei.

Afiliación

Zhang Q; Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, People's Republic of China.
Zhou R; Anhui Provincial Institute of Translational Medicine, Hefei, People's Republic of China.
Yang J; Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, People's Republic of China.
Dou C; Anhui Provincial Institute of Translational Medicine, Hefei, People's Republic of China.
Gan T; Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, People's Republic of China.
Liu F; Anhui Provincial Institute of Translational Medicine, Hefei, People's Republic of China.
Hu B; Shandong Boan Biotechnology Co., Ltd., Yantai, People's Republic of China.
Song D; Shandong Boan Biotechnology Co., Ltd., Yantai, People's Republic of China.
Lu C; Shandong Boan Biotechnology Co., Ltd., Yantai, People's Republic of China.
Hu W; Shandong Boan Biotechnology Co., Ltd., Yantai, People's Republic of China.

Infect Dis Ther ; 11(1): 405-422, 2022 Feb.

Article en En | MEDLINE | ID: mdl-34878625

Palabras clave

COVID-19; Immunogenicity; LY-CovMab; Monoclonal neutralizing antibody; Pharmacokinetics; SARS-CoV-2; Safety

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Infect Dis Ther Año: 2022 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google